Engineered fat cells (adipocytes) can suppress tumor growth in mice. Researchers modified adipocytes to produce and release IL-12, a potent anti-cancer cytokine. When these engineered fat cells were implanted near tumors in mouse models of ovarian, colorectal, and breast cancer, tumor growth was significantly inhibited. This suppression was attributed to the IL-12 stimulating an anti-tumor immune response, including increased infiltration of immune cells into the tumor microenvironment and reduced blood vessel formation within the tumor. The findings suggest engineered adipocytes could represent a novel cell therapy approach for cancer treatment.
The blog post explores the author's experience with an enlarged prostate and his journey to find relief from bothersome urinary symptoms. He details the ineffectiveness of medications like Flomax and Finasteride before undergoing a UroLift procedure. While initially successful, the UroLift's benefits diminished after a year, prompting him to consider a Transurethral Resection of the Prostate (TURP). Ultimately, he opted for a GreenLight laser TURP and reports significant improvement in his symptoms, effectively ending his "prostate trouble." He emphasizes the importance of researching different treatment options and finding a skilled urologist.
HN users discussed the complexities of prostate cancer screening and treatment. Several highlighted the overdiagnosis and overtreatment problem, citing the potential harms of biopsies and treatments like radiation and surgery for slow-growing cancers that might never cause symptoms. The PSA test's inaccuracy and tendency to lead to unnecessary interventions were also criticized. Some commenters shared personal experiences with prostate cancer, emphasizing the importance of informed decision-making and second opinions. The piece's focus on focal therapy was met with interest, but users cautioned that it's not a universal solution and still requires thorough research and consideration. A few users pointed out the emotional toll of prostate cancer diagnosis and the difficulty of navigating treatment options.
Mitochondrial transfer, the process of cells exchanging these crucial energy-producing organelles, is a newly appreciated phenomenon with significant implications for human health. While once thought rare, research now suggests it happens more frequently than previously believed, especially during stress, injury, or disease. This transfer can rescue damaged cells by providing healthy mitochondria, potentially treating conditions like stroke, heart attack, and age-related diseases. However, the long-term effects and potential risks, such as transferring mutated mitochondria or triggering immune responses, are still being investigated. Further research is needed to fully understand the mechanisms and therapeutic potential of this cellular exchange.
Hacker News users discussed the implications of mitochondrial swapping between cells, with several expressing skepticism about the research methods and the extent to which this phenomenon occurs naturally. Some questioned the artificiality of the cell cultures used and whether the observed transfer is a stress response rather than a normal physiological process. Others highlighted the potential relevance to cancer metastasis and neurodegenerative diseases, speculating on the possibility of "healthy" mitochondria rescuing damaged cells. There was interest in the evolutionary implications and whether this could be a form of intercellular communication or a mechanism for sharing resources. Some users also pointed out existing research on mitochondrial transfer in different contexts like stem cell therapy and horizontal gene transfer. The overall sentiment was a mixture of cautious optimism about the potential therapeutic applications and healthy skepticism about the current understanding of the phenomenon.
Scientists have identified a potential mechanism by which aspirin may inhibit cancer metastasis. Research suggests aspirin's anti-inflammatory effects disrupt the communication between cancer cells and platelets, which normally help cancer cells travel through the bloodstream and establish secondary tumors. By blocking a specific pathway involving the protein HMGB1, aspirin prevents platelets from shielding cancer cells from the immune system and supporting their survival in new locations. This discovery could lead to new cancer treatments or more effective use of aspirin for cancer prevention, though further research is needed.
HN commenters discuss the limitations of the study, pointing out that it's in mice, a small sample size, and doesn't establish causation. Some express skepticism about the reporting, noting that the BBC article doesn't mention the specific cancer types studied or the dose of aspirin used. Others raise concerns about the potential side effects of long-term aspirin use, like gastrointestinal bleeding. A few commenters offer alternative explanations for the observed effect, such as aspirin's anti-inflammatory properties. Several highlight the need for human trials to confirm these findings and determine safe and effective dosages. Finally, some express cautious optimism about the potential of repurposing existing drugs like aspirin for cancer treatment.
A study published in BMC Public Health found a correlation between tattoo ink exposure and increased risk of certain skin cancers (squamous cell carcinoma, basal cell carcinoma, melanoma) and lymphoma. While the study observed this association, it did not establish a causal link. Further research is needed to determine the exact mechanisms and confirm if tattoo inks directly contribute to these conditions. The study analyzed data from a large US health survey and found that individuals with tattoos reported higher rates of these cancers and lymphoma compared to those without tattoos. However, the researchers acknowledge potential confounding factors like sun exposure, skin type, and other lifestyle choices which could influence the results.
HN commenters discuss the small sample size (n=407) and the lack of control for confounding factors like socioeconomic status, sun exposure, and risky behaviors often associated with tattoos. Several express skepticism about the causal link between tattoo ink and cancer, suggesting correlation doesn't equal causation. One commenter points out that the study relies on self-reporting, which can be unreliable. Another highlights the difficulty in isolating the effects of the ink itself versus other factors related to the tattooing process, such as hygiene practices or the introduction of foreign substances into the skin. The lack of detail about the types of ink used is also criticized, as different inks contain different chemicals with varying potential risks. Overall, the consensus leans towards cautious interpretation of the study's findings due to its limitations.
Researchers at the Walter and Eliza Hall Institute have developed a promising new experimental cancer treatment using modified CAR T cells. Pre-clinical testing in mice showed the treatment successfully eliminated solid tumors and prevented their recurrence without the severe side effects typically associated with CAR T cell therapy. This breakthrough paves the way for human clinical trials, offering potential hope for a safer and more effective treatment option against solid cancers.
HN commenters express cautious optimism about the pre-clinical trial results of a new cancer treatment targeting the MCL-1 protein. Several highlight the difficulty of translating promising pre-clinical findings into effective human therapies, citing the complex and often unpredictable nature of cancer. Some question the specificity of the treatment and its potential for side effects given MCL-1's role in healthy cells. Others discuss the funding and development process for new cancer drugs, emphasizing the lengthy and expensive road to clinical trials and eventual approval. A few commenters share personal experiences with cancer and express hope for new treatment options. Overall, the sentiment is one of tempered excitement, acknowledging the early stage of the research while recognizing the potential significance of the findings.
Facing a terminal cancer diagnosis, Stanford professor Bryant Lin refused to abandon his students. Instead, he integrated his experience with esophageal cancer into his final course, "Living With Cancer," offering a uniquely personal and real-time perspective on the disease. He openly shared his treatment journey, physical struggles, and emotional reflections, providing students with invaluable insights into the medical, social, and ethical dimensions of cancer. Lin's dedication to teaching and his willingness to be vulnerable transformed his classroom into a space of shared humanity and learning, inspiring students even as he confronted his own mortality.
HN commenters discuss the Stanford professor's decision to teach a class about his cancer journey. Several praise his bravery and openness, viewing it as a powerful way to educate students and destigmatize illness. Some question the emotional toll on both the professor and the students, wondering about the appropriateness of such a personal subject in an academic setting. Others express skepticism about the framing of the NYT piece, suggesting it's overly sentimentalized. A few commenters also share their own experiences with cancer and teaching, drawing parallels to the professor's situation. The potential for triggering students facing similar challenges is also brought up, along with concerns about the blurring of lines between professional and personal life.
Eighteen years after receiving an experimental CAR T-cell therapy for neuroblastoma as a child, Emily Whitehead remains cancer-free. This marks a significant milestone for the innovative treatment, which genetically modifies a patient's own immune cells to target and destroy cancer cells. Her sustained remission offers long-term evidence of the potential for CAR T-cell therapy to cure cancers, particularly in children, and highlights the enduring impact of this groundbreaking medical advancement.
HN commenters express cautious optimism about the woman's remission after 18 years, emphasizing that it's one case and doesn't guarantee a cure for neuroblastoma. Some discuss the broader potential of CAR T-cell therapy, while acknowledging its current limitations like cost and severe side effects. A few highlight the grueling nature of the treatment and the importance of continued research and improvement. One commenter points out that the original clinical trial had only three participants, further underscoring the need for larger studies to confirm the efficacy of this approach. Several users express hope that the technology becomes more accessible and affordable in the future.
Ultra-fast, high-dose radiotherapy techniques like FLASH and proton beam therapy are showing promise in shrinking tumors while minimizing damage to surrounding healthy tissue. These methods deliver radiation in fractions of a second, potentially leveraging a phenomenon called the FLASH effect which seems to spare healthy tissue while remaining effective against cancer. While still in early stages of research and facing technical hurdles like developing equipment capable of delivering such rapid doses, these approaches could revolutionize cancer treatment, reducing side effects and treatment times compared to conventional radiotherapy.
Hacker News users discuss the potential of FLASH radiotherapy, expressing cautious optimism. Some highlight the exciting possibility of reduced side effects due to the ultra-short delivery time, potentially sparing healthy tissue. Others raise concerns about the long-term efficacy and the need for more research, particularly regarding the biological mechanisms behind FLASH's purported benefits. Several commenters mention the cost and accessibility challenges of new cancer treatments, emphasizing the importance of ensuring equitable access if FLASH proves successful. A few users with personal experience in radiation oncology offer insights into the current state of the field and the practical considerations surrounding the implementation of new technologies.
The US Food and Drug Administration (FDA) is finalizing a ban on Red Dye No. 3 in cosmetics and externally applied drugs, citing concerns over links to cancer. While the dye is already banned in most foods, this action expands the ban to cover uses like lipstick and eye shadow. This move follows decades of advocacy and pressure, including legal action by consumer groups, and builds upon previous FDA actions restricting the dye's usage.
Hacker News users discussed the FDA's ban of Red Dye No. 3, expressing skepticism about the extent of the risk and the FDA's motivations. Some questioned the evidence linking the dye to cancer, pointing to the high doses used in studies and suggesting the focus should be on broader dietary health. Others highlighted the difficulty of avoiding the dye, given its prevalence in various products. Several comments noted the long history of concern around Red Dye No. 3 and questioned why action was only being taken now. The political implications of the ban, particularly its association with Robert F. Kennedy Jr.'s campaign, were also discussed, with some suggesting it was a politically motivated decision. A few users mentioned potential alternatives and the complexities of the food coloring industry.
Summary of Comments ( 0 )
https://news.ycombinator.com/item?id=43909360
HN commenters generally express excitement about the potential of the research to treat cancer cachexia, highlighting the debilitating nature of the condition and the lack of effective therapies. Some raise concerns about scalability and cost, questioning the feasibility of personalized cell therapies for widespread use. Others point out the early stage of the research, emphasizing the need for further studies, particularly in humans, before drawing definitive conclusions. A few commenters delve into the specifics of the study, discussing the role of IL-15 signaling and the possibility of off-target effects. The potential for this approach to address other metabolic disorders is also mentioned.
The Hacker News thread for "Engineered adipocytes implantation suppresses tumor progression in cancer models" contains several comments discussing the research and its implications.
Several users express cautious optimism about the findings. One commenter highlights the potential of the approach, calling it "fascinating" and noting the shift in focus from targeting tumor cells directly to modifying the tumor microenvironment. They also acknowledge the early stage of the research, emphasizing the need for further investigation into the long-term effects and potential side effects. Another user echoes this sentiment, pointing out that while the results in mouse models are promising, translating them to humans is a significant hurdle. They also raise the crucial point that the therapy doesn't eradicate the tumor but rather slows its progression.
A recurring theme in the comments is the complexity of cancer and the challenges in developing effective treatments. One user discusses the history of cancer research, highlighting past failures and the difficulty of predicting long-term outcomes. They express hope that this research will lead to a viable treatment but also caution against over-optimism. Another commenter focuses on the heterogeneity of tumors and the potential for the treatment to be effective in some cancer types but not others.
Some comments delve into the specifics of the research. One user questions whether the engineered adipocytes differentiate into other cell types within the tumor microenvironment, potentially influencing the results. Another comment delves into the mechanism of action, specifically discussing the role of IL-12 and how it contributes to the observed anti-tumor effects. A further comment explores the potential use of this therapy in conjunction with existing treatments like chemotherapy and immunotherapy.
There's also a discussion about the broader implications of the research. One commenter points out the potential for this approach to be applied to other diseases beyond cancer, highlighting the growing interest in manipulating the microenvironment for therapeutic benefit. Another comment raises the ethical considerations of using genetically engineered cells, emphasizing the need for careful regulation and long-term monitoring.
Finally, some comments focus on the technical aspects of the research, questioning the scalability and cost-effectiveness of producing engineered adipocytes for widespread clinical use.